Close Menu

NEW YORK (360Dx) – UBS today initiated coverage of Agilent Technologies with a Buy rating and price target of $92, and Qiagen with a Neutral rating and price target of $42.

In a report to investors, UBS analyst Daniel Brennan noted that for Agilent, the investment bank's above-consensus 2019 through 2021 organic revenue forecasts are supported by durable high single-digit growth in pharma along with growth tied to the gas chromatography product cycle in the chemical and energy segment.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.